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ABSTRACT: Photodynamic therapy (PDT) is a promising
treatment strategy for malignant and nonmalignant lesions. 5-
Aminolaevulinic acid (ALA) is used as a precursor of the
photosensitizer, protoporphyrin IX (PpIX), in dermatology
and urology. However, the eﬀectiveness of ALA−PDT is
limited by the relatively poor bioavailability of ALA and rapid
conversion of PpIX to haem. The main goal of this study was
to prepare and investigate a library of single conjugates
designed to coadminister the bioactive agents ALA and
hydroxypyridinone (HPO) iron chelators. A signiﬁcant
increase in intracellular PpIX levels was observed in all cell
lines tested when compared to the administration of ALA
alone. The higher PpIX levels observed using the conjugates correlated well with the observed phototoxicity following exposure
of cells to light. Passive diﬀusion appears to be the main mechanism for the majority of ALA−HPOs investigated. This study
demonstrates that ALA−HPOs signiﬁcantly enhance phototherapeutic metabolite formation and phototoxicity.
1. INTRODUCTION
Photodynamic therapy (PDT) is based on the activation of
exogenously applied or endogenously formed photosensitizers
by visible light in the presence of molecular oxygen.
Photosensitization upon light activation results in formation
of singlet oxygen, which is a powerful oxidant, leading to the
damage of a variety of subcellular substrates and cell death.1−4
5-Aminolaevulinic acid photodynamic therapy (ALA−PDT)
utilizes the haem biosynthesis pathway to transiently produce
excess (and clinically useful) amounts of the natural
endogenous photosensitizer protoporphyrin IX (PpIX). This
is achieved by the addition of exogenous ALA, which enters the
haem biosynthesis pathway.5,6 The main advantage of ALA−
PDT is the short half-life of its photosensitizing eﬀects, which
reduces the duration of skin photosensitivity and its eﬃcacy
using topical administration.7 However, several factors aﬀect
ALA−PDT and limit its clinical potential. In particular, the
hydrophilic nature of ALA limits its rate of uptake into
neoplastic cells and/or penetration into tissue.8 Considerable
eﬀorts have been made recently to overcome the bioavailability
limitations associated with ALA, which have mainly been
centered on the development of ALA prodrugs with higher
lipophilicity, such as esters7,9−15 and peptide derivatives.16−18
In simple ester conjugates, ALA is cleaved at the C-terminus via
interaction with esterases, but in some ALA conjugates cleavage
at the N-terminus is also required via peptidases15,16 and
phosphatases.14 The methyl and hexyl esters of ALA have been
approved for topical treatment of basal cell carcinoma in both
Europe and Australia. The use of diﬀerent delivery vehicles,
such as microspheres, liposomes, conjugate antibodies, has also
been investigated.19
The stage following PpIX production in the haem pathway is
the insertion of ferrous iron (Fe2+) under the action of the
ferrochelatase to convert PpIX into haem.6 The presence of free
haem acts as a negative feedback mechanism inhibiting ALA
synthesis.6 The exogenous administration of large amounts of
ALA bypasses this negative feedback signal.20 The resultant
accumulation of PpIX within the cells is the rate-limiting step
for conversion of PpIX to haem by ferrochelatase.11,21,22 An
additional approach to achieve a greater PpIX accumulation
involves the chelation of intracellular iron. As a result, the
conversion of PpIX to haem is decreased, further enhancing the
accumulation of PpIX in the cell.7,8,22 The nonspeciﬁc
membrane-impermeable metal chelator ethylenediamine tetra-
acetic acid (EDTA) has been shown to moderately increase
PpIX levels in epithelial skin tumors in combination with
ALA.23,24 Desferrioxamine (DFO) is more eﬀective than EDTA
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at elevating PpIX in cells due to its greater aﬃnity for iron than
EDTA.25−27
In our studies using 3-hydroxypyridin-4-one chelators
(HPO), a combination of ALA and 1,2-diethyl-3-hydroxypyr-
idin-4-one (CP94, 26) in PDT proved to be an eﬀective
technique to increase the eﬃcacy of ALA−PDT within cells in
vitro and in vivo.28−31 The concept of exploiting high aﬃnity
iron(III) chelators for ferrochelatase inhibition in order to
increase the ALA−induced PpIX levels is based upon the ability
of these compounds to stimulate the oxidation of Fe2+ to Fe3+
at low concentration, with O2 acting as the oxidant. Compound
26 is a member of the hydroxypyridinone family of bidentate
iron chelators. It is particularly eﬀective at chelating intracellular
iron due to its lower molecular weight and higher lipophilicity
than either DFO or EDTA.32−35 However, coadministration of
ALA and iron chelator would be limited by the diﬀering
pharmacological properties of the two agents. In contrast, the
molecules in which ALA and HPO agents are coupled via
cleavable linkages would release the two agents following
cellular uptake. The enhanced porphyrin levels would therefore
arise principally from simultaneous delivery of the synergisti-
cally acting bioactive agents to cell. Indeed, in our previous
work, it has also been demonstrated that some ALA/HPO
conjugates are more eﬃcient than ALA and ALA in
combination with HPO for PpIX production in some tumor
cell lines.36,37
Because HPOs, such as 26, are more eﬀective at chelating
intracellular iron than desferrioxamine due to the superior cell
membrane permeability of HPOs,38 in the present work, a
range of ALA−HPO conjugates were designed and synthesized
in order to synergistically promote intracellular phototoxicity.
There is compelling evidence with regards to the important role
of the conjugation bonding, the spacers/linkers types, and
length of the spacers for ALA−PDT based on the literature and
our previous work.7,9−13,16,17,36,37 For example, Battah et al.
found that increasing the linker length in ALA dendritic
derivatives led to an enhancement of intracellular porphyrin
generation, which was ascribed to a reduction in steric
hindrance to esterase access.13 However, linkers can also aﬀect
the lipophilicity of the conjugate, which will in turn aﬀect its
bioavailability.13
The goal of this investigation was to optimize and determine
the eﬃcacy of several spacers that control the PDT of ALA−
HPO conjugates. The chosen iron chelators have similar
chemical structures to that of 2-ethyl-3-hydroxypyridin-4-one
(26) attached to ALA via a variety of links (Chart 1). The two
moieties were covalently bonded through ester bonds, which
were predicted to hydrolyze enzymatically under intracellular
conditions. The eﬃcacy of these ALA−HPO conjugates has
been investigated in various cell lines and the kinetics of PpIX
ﬂuorescence and phototoxicity monitored.
2. RESULTS AND DISCUSSION
2.1. Chemistry. The ability of ALA−HPO conjugates to
penetrate the tumor cell membrane and ease of liberating free
ALA molecule intracellularly are important factors aﬀecting the
activity of the prodrugs. To obtain ALA prodrugs with high
PpIX generation eﬃciency and high phototoxicity against
tumor cells, a range of ALA−HPO conjugates were designed:
(a) HPO has a similar structure to 26, features a ethyl group at
position 2, and is linked to ALA through diﬀerent lengths of
hydrocarbon spacers (CH2)n, n = 2−12) in compounds (7a−
7f) via readily cleavable ester bond; (b) the same HPO with
ethyl group at position 2 is linked to ALA through a triethylene
glycol spacer in compound (23); (c) the ethyl group of HPO at
position 2 was substituted with 1-hydroxylethyl in compound
(12) and a methylamino carbonyl group in compound (18),
and both groups were linked to ALA via ester bonds in these
two compounds with a (CH2)6 hydrocarbon chain; (d) hexyl-
ALA and octyl-ALA were chosen for comparison (compounds
24 and 25), respectively (Chart 1).
Preparation of ALA−HPO Conjugates 7. The synthetic
route of ALA−HPO conjugates 7 starting from ethyl maltol
(1a) is outlined in Scheme 1. The benzylation of ethyl maltol
with benzyl chloride provided 2a in 66% yield. The amino
alcohol spacers 3a, 3b, and 3c (n = 2, 4 and 6, respectively) are
commercially available, whereas 3d, 3e, and 3f (n = 8, 10 and
12, respectively) were synthesized by the Mitsunobu reaction
using triphenylphosphine (Ph3P), phthalimide, and diisopropyl
azodicarboxylate (DIPAD), followed by hydrazination. Con-
densation of 2a and amino alcohol 3 under alkaline condition
provided the 2-alkyl-substituted 3-hydroxypyridin-4-ones (4).
Chart 1. Structures of ALA−HPO Conjugates and ALA
Esters
Scheme 1. Synthesis of ALA−HPO Conjugates 7a
a(a) BnCl; (b) NH2(CH2)nOH (3); (c) H2, Pd/C, MeOH; (d) N-
Cbz-ALA (7), DCC, DMAP; (e) H2, Pd/C, EtOAc/MeOH.
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The protected pyridinones 4 were coupled with N-Cbz ALA,
which was prepared in aqueous solution at pH 8−10 at room
temperature in reasonable yield, forming an ester link using the
standard coupling agents 1,3-dicyclohexylcabodiimide (DCC)
and 4-dimethylaminopyridine (DMAP), yielding the protected
ALA−HPO conjugates 6. Deprotection of 6 was achieved by
hydrogenation at 40 psi H2 atmosphere in methanol and ethyl
acetate (1:3, by volume) in the presence of benzyl chloride to
aﬀord the hydrochlorides of ALA−HPO conjugates 7. The
clogP values of this series 7a−7f range from −1.96 to 0.91
(Table 1).
Preparation of ALA−HPO Conjugates 12 and 18. The
synthetic route of ALA−HPO conjugate 12 is presented in
Scheme 2. Conversion of the 2-ethyl group of 2a to 2-
hydroxyethyl was accomplished using selenium oxide as a
oxidizing agent in phenyl bromide with reﬂux, providing
compound 8 in 43% yield; at the same time, another oxidized
product 2-acetyl-3-(benzyloxy)-4H-pyran-4-one was detected
(11% yield). The newly formed hydroxyl group in compound 8
was subsequently protected using benzyl bromide in a two-
phase reaction using tetrabutylammonium sulfate as phase
transfer catalyst, yielding 9 in 62% yield. Compound 9 was
converted to the pyridinone 10 via condensation with 6-amino-
hexan-1-ol. Conversion of 10 to 12 was achieved using the
similar procedures to that for ALA−HPO conjugates 7
(Scheme 2). The synthesis of ALA−HPO conjugate 18 using
maltol (1b) as a starting material is shown in Scheme 3. The
methyl group in benzyl protected maltol was selectively
oxidized by selenium oxide to form an aldehyde 13, which
was further oxidized to a carboxylic acid 14 in the presence of
sodium hypochlorite and sulfamic acid.39 The carboxyl group
was activated by DCC/N-hydroxysuccimide (NHS) to form an
activated ester, which was subsequently coupled to methyl-
amine, providing a pyranone derivative 15. Insertion of the
amino alcohol spacers into the pyranone ring was achieved by
reﬂuxing the corresponding spacer with 15 in an alcoholic
solution of sodium hydroxide at pH 12 to aﬀord the pyridinone
16, which was coupled to N-Cbz ALA, providing 17, the latter
was subjected to hydrogenation, generating the ALA−HPO
conjugate 18 (Scheme 3). The two conjugates 12 and 18 are
relatively hydrophilic, the clogP values being −1.28 and −1.65,
respectively (Table 1).
Preparation of the Triethylene Glycol-Linked ALA−HPO
Conjugate 23. The amino alcohol 20 was prepared from
triethylene glycol using the Mitsunobu reaction (Scheme 4).
Table 1. ClogP and LD50 Values of ALA, ALA−HPO
Conjugates, and ALA Estersa
LD50 (μM)
compd KB MCF-7 MCF-7R ClogP
ALA 124.0 ± 5.2 131.2 ± 7.4 122.5 ± 8.2 −1.3
7a 114.6 ± 3.6 124.2 ± 5.3 122.4 ± 5.6 −1.96
7b 65.1 ± 6.3 76.5 ± 7.1 61.2 ± 3.9 −1.42
7c 5.2 ± 2.5 13.4 ± 2.6 8.1 ± 4.6 −0.41
7d 3.1 ± 1.1 10.9 ± 3.2 4.2 ± 2.2 0.60
7e 2.3 ± 0.5 8.1 ± 4.1 3.9 ± 2.4 0.73
7f 2.5 ± 0.32 12.9 ± 2.6 5.5 ± 3.1 0.91
12 24.1 ± 1.42 16.6 ± 4.4 8.4 ± 2.4 −1.28
18 107.5 ± 4.6 113.3 ± 6.5 104.5 ± 5.1 −1.65
23 19.6 ± 1.4 15.8 ± 5.1 11.3 ± 3.8 −2.37
24 2.6 ± 0.26 9.3 ± 0.07 8.4 ± 0.12 0.83
25 ND ND ND 1.84
aClogP values were obtained using an Internet software (http://www.
molinspiration.com/cgi-bin/properties). LD50 values were calculated
from two sets of phototoxicity experiments in KB, MCF-7, and MCF-
7R cell lines after 4 h incubation using concentrations between 20 and
100 μM for (ALA, 7a, 7b, 12, and 23) and concentrations between 2
and 10 μM for (7c, 7d, 7e, and 7f) prodrugs and irradiated with 2.5 J/
cm2.
Scheme 2. Synthesis of ALA−HPO Conjugate 12a
a(a) SeO2; (b) BnBr; (c) NH2(CH2)6OH; (d) N-Cbz-ALA (7), DCC,
DMAP; (e) H2, Pd/C.
Scheme 3. Synthesis of ALA−HPO Conjugate 18a
a(a) (i) BnCl, (ii) SeO2; (b) NH2SO3H, NaClO2; (c) (i) DCC, NHS,
(ii) MeNH2; (d) NH2(CH2)6OH; (e) N-Cbz-ALA (7), DCC, DMAP;
(f) H2, Pd/C.
Scheme 4. Synthesis of ALA−HPO Conjugate 23a
a(a) HO(CH2CH2O)3H, Ph3P, DIPAD; (b) NH2NH2; (c) 2a; (d) N-
Cbz-ALA (7), DCC, DMAP; (e) H2, Pd/C.
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Condensation of 20 with the benzyl protected ethyl maltol (2a)
yielded the derivative 21. Conjugation with protected ALA
using similar methods to that described for the hydrocarbon
linked molecule (4) yielded the desired ester (22), which upon
hydrogenation yielded the ALA−HPO conjugate (23) (Scheme
4). This is the most hydrophilic compound of the series with a
clogP value of −2.37 (Table 1).
2.2. Biological Evaluation. MCF-7 cells (human breast
adenocarcinoma) and MCF-7R cells (doxorubicin resistant
subline, MCF-7/DXR) were chosen to assess the eﬃcacy of the
newly synthesized ALA−HPO conjugates to generate the
photoactive, ﬂuorescent photosensitizer PpIX. PDT has been
proposed in several studies as an alternative in overcoming
multidrug resistance (MDR) phenotype.10,40
Therefore, the goal was to compare the accumulation and
photosensitization of PpIX in MCF-7 human breast adeno-
carcinoma cells and its doxorubicin MDR resistant counterpart,
which is characterized by the overexpression of P-gp. Human
KB cells were also selected, which are derived from an oral
epidermal squamous cell carcinoma of the mouth. ALA has
been used for head and neck cancer, both topically and with
oral administration.41,42
2.2.1. Concentration Dependence Proﬁle. The ﬂuorescence
intensity of PpIX generated in MCF-7R cells after exposure of
ALA or HPO−ALA conjugates for 6 h is presented in Figure 1.
Fluorescence spectra were consistent with the production of
PpIX, and the peak emission at 635 nm was recorded for each
compound. The protophyrin PpIX ﬂuorescence induced by
exposure to the majority of ALA−HPO conjugates indicated an
eﬃcient internalization and metabolism within all the
investigated cell lines. PpIX production exhibited a dose
dependent response for all ALA−HPO single conjugates.
Porphyrin generation was enhanced over a range of
concentrations between (1−100 μM) after 6 h incubation for
the compounds with long hydrocarbon spacers between ALA
and HPO with the ethyl group at position 2 (Figure 1). PpIX
generation was elevated signiﬁcantly from 7b (n = 4 clogP
−1.42) to 7f (n = 12, clogP 0.91) by a factor of about 2−25,
reaching the maximum level with compound 7e (n = 10), while
compound 7a failed to increase PpIX greatly as compared to
that produced with ALA itself at the highest concentration (100
μM). This eﬀect is attributed to the graduation of lipophilicity
and the changes in steric hindrance around the ester hydrolysis
sites.12 The presence of the HPO moiety within the conjugates
enhanced the ﬂuorescence intensities for 7c, 7d, and 7e
compounds when compared with those of compounds 24 and
25, having same esters (hexyl and octyl ALA esters).43 The
ALA−HPO featuring the triethylene glycol spacer 23 with a
clogP value of −2.37 elevated PpIX production levels to over
20-fold higher than ALA at 100 μM. PpIX accumulation
induced by HPOs with the side chain, 2-ethyl (compound 7c),
was superior to those HPOs with the modiﬁed side groups
(hydroxyethyl and amido −CONHCH3) of compounds 12 and
18, respectively. Although compounds 7c, 12, and 18 were
linked to ALA via the same spacers (CH2)6, compound 7c
produced PpIX ﬂuorescence >15-fold that of ALA, compound
12 yielded >10-fold, while compound 18 failed to enhance the
level of PpIX production with respect to PpIX-ALA.
2.2.2. Fluorescence Kinetics. ALA−HPOs single conjugates
were clearly more eﬃcient than ALA with respect to PpIX
generation over an incubation period up to 24 h in KB cell lines
(Figure 2). PpIX ﬂuorescence kinetics of ALA−HPOs with
long hydrocarbon spacers, (7d, 7e, and 7f) continued to exhibit
signiﬁcant enhancement in PpIX generation over time.
The compounds with longer hydrocarbon spacers demon-
strated eﬃcient PpIX production, which was further enhanced
by the presence of HPO (with a similar structure to 26) over
incubation time ranging between 2 and 24 h (Figure 2). The
existence of HPO at the other end of the spacers (n = 6, n = 8,
n = 10) probably led to a reduction of the toxicity of the spacers
on ester formation with ALA. On the other hand, HPO could
boost the penetration of conjugates through the cell membrane.
ALA esters with hydrocarbons over n = 6 have reduced
bioavailabilities as a result of being trapped within
bilayers.11,12,44 There have been many reports detailing the
mechanistic uptake of ALA and ALA esters, which showed that
the mechanism of uptake of ALA is via active transport and its
esters adopt a passive diﬀusion pathway.7,9−12
We have compared the production of PpIX in the KB cell
line at 37 °C and 4 °C to investigate whether ALA and ALA−
HPOs are transported into the cell primarily by active and
passive transport mechanisms, respectively. An active transport
system would be signiﬁcantly inhibited by lowering the
temperature to 4 °C, whereas involvement of passive transport
would still enable uptake at lower temperatures. The results
presented in Figure 3 show that incorporation of ALA and
ALA−HPOs into KB cells is temperature dependent: i.e,. when
ALA−HPOs uptake was measured at 4 °C, a marginal
reduction of PpIX ﬂuorescence was observed, up to ≈5% for
most of ALA−HPOs, except PpIX generated by 12, which
Figure 1. PpIX ﬂuorescence intensity recorded in the MCF-7R cell
line after exposure to diﬀerent concentrations of ALA or ALA−HPOs
or hexyl and octyl ALA ester prodrugs. The results were obtained after
6 h incubation at 37 °C.
Figure 2. PpIX ﬂuorescence time course in KB cell line after exposure
to ALA (50 μM) or ALA−HPO prodrugs (50 μM). Cells were
incubated at 37 °C in a CO2 humidiﬁed incubator.
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impaired by ca. ≈50%. In contrast, PpIX ﬂuorescence produced
by ALA was found to be signiﬁcantly reduced up to 90%, which
is in good agreement with previous studies.45 Thus, we can
conclude that an incorporation of ALA and ALA−HPOs into
the KB cells (and by extrapolation the MCF-7 and MCF7R cell
lines also) involves two diﬀerent mechanistic pathways, with
passive diﬀusion predominating as the main pathway for ALA−
HPOs single conjugates.
A comparison of PpIX ﬂuorescence kinetics produced upon a
24 h time-course treatment of compounds 7c, 12, and 18
highlighted the signiﬁcant role of the HPO in PpIX production
(each compound contained a hexyl linker to ALA but diﬀerent
structures of HPO). Compound 12 exhibited higher porphyrin
ﬂuorescence levels than 7c, while compound 18 was not
eﬀective at enhancing PpIX accumulation. Surprisingly, the
hydrophilic conjugate 23, with a triethylenglycol spacer, was
found to be highly eﬀective in all cell lines, particularly at longer
time points (Figures 1, 2, and 4).
For compounds 7, there is a clear relationship between the
length of the hydrocarbon linkers and PpIX accumulation
(Figures 1, 2 and 4), the eﬀect increasing over the range n = 2
to n = 10, whereas with n = 12 a relative decline was found in
PpIX accumulation, probably due to the relatively low solubility
of this compound. The optimum compound (7e) has a clogP
value of 0.73. The compounds 7d, 7e, 7f, and 23 are all more
eﬀective than the hexyl- and octyl esters of ALA (24 and 25)
(Figure 1).
The length of the hydrocarbon link is also directly correlated
with the clogP values, and in view of their molecular size and
range of clogP values, it is most probable that they gain access
to the cytoplasm of cells by nonfacilitated diﬀusion.12 However,
the high eﬃciency of 23 (clogP = −2.37) would indicate that
this molecule is a substrate for transport, a possibility which is
currently under investigation.
Although coadministration of ALA and HPOs separately (ie
without conjugation) was found to enhance PpIX levels when
compared to ALA alone, the additive eﬀect was signiﬁcantly
weaker than when the related conjugates were investigated as
shown in Figure 4. This corresponds well with our previous
studies in cells using coincubation of ALA and 26.27 The use of
26 in combination with ALA and methyl ALA ester also
produced signiﬁcant enhancements of PpIX ﬂuorescence in
human glioma cells. At the highest concentrations of each
prodrug, 26 enhanced PpIX ﬂuorescence signiﬁcantly at 3 h for
ALA and by more than 50% at 6 h for ALA methyl ester. In our
study, an increase in PpIX levels by approximately a factor of 2
was observed in both MCF-7 and MCF-7R cell lines in the
presence of the conjugates when compared to the equivalent
separate additions after 6 h incubation (Figure 4A). The
synergistic eﬀect on PpIX enhancement was also conﬁrmed in
KB cells over a 24 h time course study, employing ALA−HPO
conjugates compared to coadministered ALA and HPOs. There
were 2−3-fold increases in PpIX production as a result of
ALA−HPO conjugate incubation over the coadministered ALA
and HPOs as a mixture, particularly at the longer incubation
times of 6 and 24 h (Figure 4B).
ALA−HPO conjugates developed in the present inves-
tigation were found to be more eﬀective in PpIX production
than our previously reported compounds, in which ALA moiety
was coupled to HPO moiety via an amide linkage.37 For
instance, after incubation with KB cells for 24 h, conjugates 7d,
7e, and 7f (50 μM) could produce PpIX level with 8-, 10.2-,
and 9.2-fold higher than ALA, whereas the best compound in
the previous study could only generate 2.9-fold higher
porphyrin levels than ALA.37 This is probably due to the fact
that esterase activity in cells is relatively high, thus rapidly
generating free ALA and HPO while peptidase activity in cells
is at a relatively lower level. The relative solubility of the
compounds in the cell culture medium with the ester linkage
was much higher than with the amide linkage, which may also
have adversely aﬀected the eﬃciency of the amide compounds.
Figure 3. PpIX ﬂuorescence produced by ALA or ALA−HPO
prodrugs (500 μM), KB cells preincubated at 4 °C/1 h, and cells
incubated only at 37 °C/1 h, then both were further incubated at 37
°C for 4 h, humidiﬁed with 5% CO2.
Figure 4. (A) PpIX ﬂuorescence production recorded in MCF-7 and
MCF-7R cell lines after exposure to diﬀerent ALA−HPOs (50 μM) in
comparison to PpIX ﬂuorescence produced by incubation of 50 μM
ALA and HPOs as a 1:1 mixture. The results were obtained after 6 h
incubation at 37 °C. (B) Time-course proﬁle of PpIX ﬂuorescence
production recorded in KB cells after exposure to 100 μM ALA, ALA−
HPOs conjugates, or (ALA + HPO) mixture incubated at 37 °C. 5c: 2-
ethyl-3-hydroxy-1-(6-hydroxyhexyl)pyridin-4(1H)-one. 5d: 2-ethyl-3-
hydroxy-1-(8-hydroxyoctyl)pyridin-4(1H)-one. 5e: 2-ethyl-3-hydroxy-
1-(10-hydroxydecyl)pyridin-4(1H)-one. 5f: 2-ethyl-3-hydroxy-1-(12-
hydroxydodecyl)pyridin-4(1H)-one. 21b: 1-(2-(2-(2-hydroxyethoxy)-
ethoxy)ethyl)-2-ethyl-3-hydroxypyridin-4(1H)-one.
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Uehlinger et al. investigated ALA and a range of ALA esters
(methyl, ethyl, butyl, hexyl, octyl, and cyclo-hexyl esters) for
the eﬃcacy in producing PpIX in some tumor cell lines (A549,
T24, J82, and BEAS-2B cells) and found that in most cell lines
ALA hexyl ester showed the most eﬃcient PpIX formation.11
Wu et al. also demonstrates that the cellular PpIX content in 1
mM ALA incubated nasopharyngeal carcinoma (NPC) cells is
similar to that in 0.03 mM ALA hexyl ester incubated cells,
reﬂecting that ALA hexyl ester is more eﬃcient than ALA for
inducing PpIX production.41 However, in the present study,
compounds 7c, 7d, 7e, and 7f were demonstrated to be even
more eﬃcient in PpIX formation than the ALA hexyl ester (24)
(Figure 1).
Intracellular PpIX ﬂuorescence of PAM212 keratinocyte cells
has been reported to be enhanced by a factor of 5 after 6 h
incubation with 0.01 mM of an ALA−peptide conjugate, Ac-L-
Phe−ALA−OMe, compared with ALA at the same concen-
tration, where the amino acid is conjugated at the N-terminus
of ALA.16 More extensive investigation of peptide prodrugs of
ALA (Ac-Xaa−ALA−OR, where Xaa is an α-amino acid)
indicated that some of the peptide prodrugs are more eﬃcient
in inducing PpIX accumulation than ALA in PAM212 and also
A549 and Caco-2 cell lines.17 For instance, at 0.1 mM, after
incubation with PAM212 keratinocyte cells for 6 h, peptide
prodrugs Ac-L-Leu−ALA−OMe, Ac-L-Phe−ALA−OMe, Ac-L-
GluOBu−t-ALA−OMe and Ac-L-Phe−Met−OMe could pro-
duce PpIX level with 7.5-, 4.4-, 6.5-, and 5.9-fold higher than
ALA.17
Recently, Babic ̌ et al. have reported that two ALA hexyl ester
analogues, P-ALA−Hex and PSI-ALA−Hex, which were
obtained by modiﬁcation of the N-terminus amino group,
displayed reduced acute toxicity compared to the ALA hexyl
ester with superior dose response proﬁles of protoporphyrin IX
synthesis and ﬂuorescence intensity in human glioblastoma
cells in vitro.14
2.2.3. Phototoxicity Studies. The phototoxicity of ALA and
ALA−HPO conjugates, incubated with tumor cells for 4 h and
irradiated with blue light (2.5 J/cm2), was investigated over a
range of concentrations between 2 and 100 μM. The data for
KB cells are presented in Figure 5. The percentages of cell
survival with respect to control cells (without compounds)
were calculated for various concentrations of investigated
compounds. In agreement with the data from the PpIX
ﬂuorescence experiments, the ALA−HPO conjugates that
exhibited a marked enhancement of PpIX ﬂuorescence also
exhibited high phototoxicity. In general, compounds 7c, 7d, 7e,
7f, and 23 were found to be the most phototoxic compounds at
low concentrations.
The LD50 values (at 2.5 J/cm
2), calculated from Figure 5, are
presented in Table 1. The values for 7d, 7e, and 7f are between
2.3 μM and 12.9 μM for all investigated cell lines, in contrast to
the much higher value of 100 μM for ALA. For 23, the LD50
values were somewhat higher, ranging between 11.3 and 19.6
μM. The LD50 value of the hexyl ester of ALA (24) was found
to be similar to that of 7e. Again, ALA−HPO conjugates in the
present investigation were more phototoxic upon exposure to
light than our previously reported compounds. For instance,
after the incubation of KB cells with 7d, 7e, and 7f (10 μM),
followed by illumination, the survival percentages of KB cells
were under 6%, while the survival percentages of KB cells
incubated with the previously reported best ALA−HPO
compound (200 μM) was 7.8%.37 The results of phototoxicity
of ALA−HPO conjugates were in accordance with those of
relative PpIX generation.
Phototoxicity was both drug concentration and irradiation
dose dependent. Our results for the ALA hexyl ester are in
accord with previous studies. For example, the hexyl ester was
much more phototoxic than ALA against nasopharyngeal
carcinoma (NPC) cells.41 To achieve an 80% death rate
(LD80), 0.75 mM ALA and 6 J/cm
2 light dose were required,
while only 0.03 mM ALA hexyl ester and 4 J/cm2 light dose
were needed. In terms of overall photodynamic dose, the ALA
hexyl ester is about 40 times more potent than ALA in cell
inactivation.41 Although iron can aﬀect the generation of ROS
through redox processes, the high production of PpIX through
the use of HPOs and improved PDT potency may predominate
over any secondary factors related to the ability of iron to
catalyze ROS generation/cascades following PpIX-induced
PDT. Moreover, despite the reduction of iron availability,
thereby increasing PpIX accumulation, other transition metals
and freshly released labile iron may preserve the ROS cascades
via Fenton reactions.46
2.2.4. Cell Viability and Dark Toxicity. The “dark” toxicity
(namely, the cytotoxicity in the absence of irradiation) of the
ALA−HPOs conjugates was also evaluated in the KB cells
(Figure 6). The data indicated that there was no appreciable
toxicity found for ALA or all the investigated compounds at 200
μM after 4 h or 24 h incubation.
The structural conjugates, where ALA is at one end and
HPO moieties on the other end of the spacers, do not appear to
induce signiﬁcantly higher dark toxicity than ALA itself. In
contrast, ALA ester derivatives, i.e., hexyl-ALA (24) and octyl-
Figure 5. Phototoxicity over a range of ALA and ALA−HPO
concentrations after 4 h incubation with the KB cell line, irradiated by
2.5 J/cm2 blue light.
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ALA (25) showed signiﬁcant dark toxicity (9% and 14% cell
survival, respectively, at the lower concentration of 100 μM
after 4 h of incubation). The incubation of ALA−HPO
conjugates for 24 h did not aﬀect the cell viability more than a 4
h incubation. However, almost no cells survived after 24 h
incubation with hexyl-ALA and octyl-ALA. It also appears with
this assay that HPOs with the spacers n = 6 or more elicit no
chemical toxicity to the cells after cleavage and releasing ALA.
The much lower dark toxicity of the HPO conjugate, albeit in a
tumor cell line, is a signiﬁcant ﬁnding in respect to the prodrug
metabolism, particularly if it is to be considered for systemic
administration, however, further in vivo studies will be required
to validate lower dark toxicities.
2.2.5. Intracellular Prodrug Quantitative Determination.
The cellular uptake of the prodrugs and their intracellular
conversion to ALA was assessed by quantitative determination
of ALA using a HPLC-based ﬂuorescence method. We adopted
a previously reported derivatization method.17,45,47,48 A higher
accumulation of ALA was observed after 2 h incubation at 100
μM, particularly in KB and MCF-7R cells using the conjugates
(Figure 7A). For example, 6- and 8-fold enhancements with 7d
and 7e were observed with respect to ALA itself. These results
were largely reﬂected in the intracellular PpIX levels measured
at 24 h following 2 h incubation by fresh medium without ALA
or prodrugs (Figure 7B).
The ﬂuorescence intensity of PpIX in MCF-7R, which is a
chemotherapy resistant breast cancer tumor cell line, elicited
higher porphyrin levels than in the MCF-7 nonresistant
counterpart, for the majority of ALA−HPO compounds.
Malik and co-workers have also demonstrated that MCF-7R,
doxorubicin resistant tumor cells, are capable of producing
higher levels of porphyrins than sensitive MCF-7 cells due to
the low expression of the enzyme ferrochelatase in combination
with high mitochondrial activity.40 As found in the present
study, higher PpIX levels than the doxorubicin sensitive MCF-7
cells were also observed.
3. CONCLUSIONS
ALA−PDT provides a promising therapy for many types of
cancer, but it is important to improve its eﬃciency when ALA is
administered systemically and intravenously in order to
overcome ineﬃcient cell uptake and conversion to PpIX. Iron
chelating agents have been demonstrated to be eﬀective at
improving ALA−PDT by increasing the cellular PpIX
accumulation. In the present study, a series of ALA−HPO
conjugates were synthesized and tested in three cells lines. All
ALA−HPO conjugates showed signiﬁcantly elevated cellular
PpIX accumulation in KB, MCF-7, and MCF-7R cell lines
when compared to ALA and a combination of ALA with the
corresponding HPO. Overall, compound 7e, with a linker of
(CH2)10, was found to be the most eﬀective in both
enhancement of cellular PpIX levels and tumor cell photo-
toxicity, with comparable eﬃcacy to the ALA hexyl ester.
4. EXPERIMENTAL SECTION
4.1. General. 1H and 13C NMR were recorded on a Jeol EX 270
MHz spectrometer (Jeol Ltd., Toxyo, Japan), or on Bruker Avance 400
or Bruker Avance 500 spectrometer. Chemical shifts are quoted in
ppm measured downﬁeld relative to TMS. Mass spectra were obtained
using a EI/CI (electroionization/chemical ionization). Analytical thin
layer chromatography was carried out using Adsorbentien, aluminum-
backed, silica-coated plates (VWR, Germany) which were visualized
using ultraviolet light (254 nm). Column chromatography was carried
out using Alfa Aester silica gel (220−440 mesh ﬂash grade). High
performance liquid chromatography (HPLC) was performed on a Si
(55w) 250 2.1 mm column attached to a Agilent instrument (Agilent,
Life Sciences & Chemical Analysis Group, UK). All the chemicals were
purchased from Aldrich, Fisher, Alfa Aester and Aladdin, and used
without further puriﬁcation unless otherwise stated. Analytical analysis
was carried out by electrospray (ES) instrument (Quattro Premier XE,
Micromass Technologies) which coupled to high performance liquid
chromatograpy (HPLC, Waters/AcQuity Ultrapreformance LC,
Waters, Manchester, UK). Electrospray ionization (ESI) mass spectra
were obtained by infusing samples into an LCQ Deca XP ion trap
instrument. High resolution mass spectra (HRMS) were determined
on Waters QTOF micro. The purity of ALA−HPO conjugates was
determined by analytical HPLC (Agilent system 1100) coupled with
UV−vis/DAD (diode array detector) using C18 reverse-phase column
[HYPERSIL (5 μm, 2.1 mm × 150 mm)]. The total run was
Figure 6. Dark toxicity of ALA, ALA−HPOs, and hexyl-ALA in KB
cells incubated for 4 h without irradiation, then continued for 24 h
after removal of the prodrugs.
Figure 7. (A) Chemically extracted cellular concentrations per mg
protein of intracellular ALA or ALA−HPOs with celLytic after 2 h
incubation at 100 μM. (B) PpIX cellular concentrations per mg
protein measured at 24 h by chemical extraction using celLytic
following 2 h incubation with ALA and ALA−HPO conjugates at 37
°C.
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monitored with UV detector at two wavelengths 268 and 282 nm. The
purities of all the AlA-HPO conjugates were over 95%.
4.2. Synthetic Procedures. 4.2.1. N-Benzyloxycarbonyl-5-
aminolevulinic Acid (N-Cbz ALA). 5-Aminolaevulinic acid (0.22 g,
1.30 mmol) was dissolved in water (3 mL) and the solution was
adjusted to pH 8−10 with sodium carbonate solution. N-
Benzyloxycarbonyl chloride (0.30 mL, 1.40 mmol) was dissolved in
dioxane (3 mL) and added to the mixture. After 18 h at room
temperature, the solvents were removed in vacuum and 0.1 M of
sodium hydroxide (20 mL) was added. The mixture was washed with
diethyl ether three times. The aqueous layer was neutralized to pH 6,
and the product was extracted with dichloromethane (5 × 20 mL).
The organic layers were combined, dried with Na2SO4, and evaporated
to yield the product as thick oil (0.18 g, 52%). 1H NMR (270 MHz,
CDCl3) δ 2.73 (m, 4H, CH2), 4.10 (s, 2H, CH2), 5.12 (s, 2H, CH2),
5.45 (br, 1H, NH), 7.31 (m, 5H, Ph). 13C NMR (67.5 MHz, CDCl3) δ
27.02, 34.20, 46.61, 65.54, 71.33, 127.66, 127.86, 128.94, 138.31,
155.00, 171.82. ESI-MS: m/z 264 ([M − H]−).
4.2.2. 3-(Benzyloxy)-2-ethyl-4H-pyran-4-one (2a). To a solution of
ethyl maltol (84 g, 0.6 mol) in methanol (300 mL) was added NaOH
solution (26.4 g in 80 mL of H2O). The mixture was heated to reﬂux,
and benzyl bromide (85.6 mL, 0.72 mol) was added dropwise over a 2
h period. The solution was maintained at 60−65 °C overnight. NaBr
was removed by ﬁltration, and the ﬁltrate was concentrated.
Dichloromethane (400 mL) was added to the residue and washed
with 5% NaOH solution (3 × 250 mL) and H2O (2 × 300 mL) and
dried over anhydrous Na2SO4. After removal of the solvent, diethyl
ether (100 mL) was added to the residue and allowed to stand to 4 °C.
The product was obtained as white crystals (91.2 g, 66%). 1H NMR
(CDCl3, 400 MHz) δ 0.98 (t, J = 7.6 Hz, 3H, CH3), 2.50 (q, J = 7.6
Hz, 2H, CH2), 5.17 (s, 2H, CH2), 6.37 (d, J = 5.6 Hz, 1H, C5-H in
pyridinone), 7.30−7.41 (m, 5H, Ph), 7.63 (d, J = 5.6 Hz, 1H, C6-H in
pyridinone). ESI-MS: m/z 231 ([M + H]+).
4.2.3. General Synthetic Procedure for Amino Alcohols (3). 8-
Aminooctan-1-ol (3d). To a mixture of 1,8-octanediol (13.3 g, 91
mmol), phthalimide (8.92g, 60.6 mmol), and triphenylphosphine
(15.89g, 60.6 mmol) in tetrahydrofuran (THF) (150 mL), cooled on
an ice-bath, was added dropwise diisopropyl azodicarboxylate
(DIPAD) (12.25 g, 60.0 mmol) over a period of 1 h. The mixture
was stirred at room temperature overnight. After removal of the
solvent, the residue was puriﬁed by column chromatography using
ethyl acetate/cyclohexane (1:2) as an eluent to obtain 2-(8-
hydroxyoctyl)isoindoline-1,3-dione (3d′) as a white solid (13.2 g,
79%). 1H NMR (CDCl3, 400 MHz) δ 1.32 (m, 8H, CH2), 1.53 (m,
2H, CH2), 1.65 (m, 2H, CH2), 3.61 (t, J = 6.5 Hz, 2H, CH2), 3.66 (t, J
= 7.5 Hz, 2H, CH2), 7.69 (m, 2H, Ph), 7.82 (m, 2H, Ph). ESI-MS: m/
z 276 ([M + H]+), 298 ([M + Na]+).
To a solution of 3d′ (12.5 g, 45.5 mmol) in 95% ethanol (150 mL)
was added 50% hydrazine (4.35g in 15 mL H2O, 68.2 mmol). The
mixture was reﬂuxed for 3 h, and then 10 M HCl (15 mL) was added.
Reﬂux was continued for a further 15 min, cooled with an ice-bath, and
then ﬁltered. The ﬁltrate was concentrated, and 15 mL of water was
added and washed with diethyl ether. The aqueous layer was adjusted
to pH 12 with 10 M NaOH and then extracted with dichloromethane
(5 × 120 mL). The combined organic layer was dried over anhydrous
Na2SO4. After removal of the solvent, 8-aminooctan-1-ol (3d) was
obtained as a white solid (5.41g, 82%). 1H NMR (CDCl3, 500 MHz) δ
1.32 (m, 8H, CH2), 1.45 (m, 2H, CH2), 1.56 (m, 2H, CH2), 2.58 (t, J
= 7.0 Hz, 2H, CH2), 2.68 (t, J = 7.0 Hz, 2H, CH2), 3.63 (t, J = 6.5 Hz,
2H, CH2). ESI-MS: m/z 146 ([M + H]
+).
2-(10-Hydroxydecyl)isoindoline-1,3-dione (3e′). 1H NMR
(CDCl3, 500 MHz) δ 1.25 (m, 10H, CH2), 1.31 (m, 2H, CH2),
1.55 (m, 2H, CH2), 1.66 (m, 2H, CH2), 3.63 (t, J = 6.5 Hz, 2H, CH2),
3.67 (t, J = 7.5 Hz, 2H, CH2), 7.70 (m, 2H, Ph), 7.83 (m, 2H, Ph).
ESI-MS: m/z 304 ([M + H]+), 326 ([M + Na]+).
10-Aminodecan-1-ol (3e). 1H NMR (CDCl3, 500 MHz) δ 1.28 (m,
10H, CH2), 1.42 (m, 4H, CH2), 1.55 (m, 2H, CH2), 2.67 (t, J = 7.0
Hz, 2H, CH2), 3.62 (t, J = 6.5 Hz, 2H, CH2). ESI-MS: m/z 174 ([M +
H]+).
2-(12-Hydroxydodecyl)isoindoline-1,3-dione (3f′). 1H NMR
(CDCl3, 500 MHz) δ 1.26 (m, 16H, CH2), 1.32 (m, 2H, CH2),
1.66 (m, 2H, CH2), 3.63 (t, J = 6.5 Hz, 2H, CH2), 3.67 (t, J = 7.5 Hz,
2H, CH2), 7.70 (m, 2H, Ph), 7.84 (m, 2H, Ph). ESI-MS: m/z 332 ([M
+ H]+), 354 ([M + Na]+).
12-Aminododecan-1-ol (3f). 1H NMR (CDCl3, 500 MHz) δ 1.27
(m, 16H, CH2), 1.43 (m, 2H, CH2), 1.55 (m, 2H, CH2), 2.67 (t, J =
7.0 Hz, 2H, CH2), 3.62 (t, J = 6.5 Hz, 2H, CH2). ESI-MS: m/z 202
([M + H]+).
4.2.4. General Synthetic Procedure for Hydroxypyridinones (4). 3-
(Benzyloxy)-2-ethyl-1-(2-hydroxyethyl)pyridin-4(1H)-one (4a). Com-
pound 2a (4.6 g, 20 mmol) was dissolved in ethanol (30 mL)/H2O(30
mL), followed by the addition of ethanolamine (3.05g, 50 mmol) and
2 M NaOH solution (2 mL). The mixture was reﬂuxed for 18 h. After
cooling to room temperature, the solution was adjusted to pH 1 with
concentrated hydrochloric acid and then concentrated to half volume.
Then 50 mL of H2O was added. The solution was washed with diethyl
ether (2 × 50 mL), adjusted to pH 9 with 10 M NaOH, and extracted
with DCM (3 × 50 mL). The combined organic layers were dried over
anhydrous Na2SO4. After removal of the solvent, 4a was obtained by
crystallization from ethyl acetate as yellow crystals (4.06g, 74%). 1H
NMR (CDCl3, 400 MHz) δ 0.96 (t, J = 7.6 Hz, 3H, CH3), 2.68 (q, J =
7.6 Hz, 2H, CH2), 3.86 (m, 2H, CH2), 3.90 (m, 2H, CH2), 5.06 (s,
2H, CH2), 6.15 (d, J = 7.4 Hz, 1H, C5-H in pyridinone), 7.30−7.40
(m, 4H, Ph and buried C6-H in pyridinone), 7.42 (m, 2H, Ph). ESI-
MS: m/z 274 ([M + H]+), 296 ([M + Na]+).
3-(Benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one (4b).
Yield 69%. 1H NMR (CDCl3, 400 MHz) δ 1.02 (t, J = 7.6 Hz, 3H,
CH3), 1.54 (m, 2H, CH2), 1.78 (m, 2H, CH2), 2.57 (q, J = 7.6 Hz, 2H,
CH2), 3.66 (t, J = 6.0 Hz, 2H, CH2), 3.82 (t, J = 7.6 Hz, 2H, CH2),
5.22 (s, 2H, CH2), 6.36 (d, J = 7.6 Hz, 1H, C5-H in pyridinone), 7.25
(d, J = 7.6 Hz, 1H, C6-H in pyridinone), 7.28−7.35 (m, 3H, Ph), 7.41
(m, 2H, Ph). ESI-MS: m/z 302 ([M + H]+), 324 ([M + Na]+).
3-(Benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one (4c).
Yield 79%. 1H NMR (CDCl3, 400 MHz) δ 1.03 (t, J = 7.6 Hz, 3H,
CH3), 1.30−1.44 (m, 4H, CH2), 1.56 (m, 2H, CH2), 1.67 (m, 2H,
CH2), 2.56 (q, J = 7.6 Hz, 2H, CH2), 3.64 (t, J = 6.4 Hz, 2H, CH2),
3.75 (t, J = 7.6 Hz, 2H, CH2), 5.26 (s, 2H, CH2), 6.41 (d, J = 7.6 Hz,
1H, C5-H in pyridinone), 7.18 (d, J = 7.6 Hz, 1H, C6-H in
pyridinone), 7.27−7.35 (m, 3H, Ph), 7.42 (m, 2H, Ph). ESI-MS: m/z
330 ([M + H]+), 352 ([M + Na]+).
3-(Benzyloxy)-2-ethyl-1-(8-hydroxyoctyl)pyridin-4(1H)-one (4d).
Yield 67%. 1H NMR (CDCl3, 400 MHz) δ 1.03 (t, J = 7.6 Hz, 3H,
CH3), 1.32 (m, 8H, CH2), 1.56 (m, 2H, CH2), 1.66 (m, 2H, CH2),
2.57 (q, J = 7.6 Hz, 2H, CH2), 3.64 (t, J = 6.6 Hz, 2H, CH2), 3.74 (t, J
= 7.6 Hz, 2H, CH2), 5.28 (s, 2H, CH2), 6.43 (d, J = 7.6 Hz, 1H, C5-H
in pyridinone), 7.17 (d, J = 7.6 Hz, 1H, C6-H in pyridinone), 7.29−
7.35 (m, 3H, Ph), 7.43 (m, 2H, Ph). ESI-MS: m/z 358 ([M + H]+),
380 ([M + Na]+).
3-(Benzyloxy)-2-ethyl-1-(10-hydroxydecyl)pyridin-4(1H)-one (4e).
Yield 63%. 1H NMR (CDCl3, 500 MHz) δ 1.04 (t, J = 7.5 Hz, 3H,
CH3), 1.29 (m, 10H, CH2), 1.55 (m, 2H, CH2), 1.66 (m, 4H, CH2),
2.57 (q, J = 7.5 Hz, 2H, CH2), 3.64 (t, J = 6.5 Hz, 2H, CH2), 3.74 (t, J
= 7.5 Hz, 2H, CH2), 5.29 (s, 2H, CH2), 6.42 (d, J = 7.5 Hz, 1H, C5-H
in pyridinone), 7.17 (d, J = 7.5 Hz, 1H, C6-H in pyridinone), 7.29−
7.35 (m, 3H, Ph), 7.44 (m, 2H, Ph). ESI-MS: m/z 386 ([M + H]+),
408 ([M + Na]+).
3-(Benzyloxy)-2-ethyl-1-(12-hydroxydodecyl)pyridin-4(1H)-one
(4f). Yield 62%. 1H NMR (CDCl3, 500 MHz) δ 1.04 (t, J = 7.5 Hz,
3H, CH3), 1.28 (m, 16H, CH2), 1.55 (m, 2H, CH2), 1.66 (m, 2H,
CH2), 2.57 (q, J = 7.5 Hz, 2H, CH2), 3.64 (t, J = 6.5 Hz, 2H, CH2),
3.74 (t, J = 7.5 Hz, 2H, CH2), 5.28 (s, 2H, CH2), 6.42 (d, J = 7.5 Hz,
1H, C5-H in pyridinone), 7.17 (d, J = 7.5 Hz, 1H, C6-H in
pyridinone), 7.29−7.35 (m, 3H, Ph), 7.43 (m, 2H, Ph). ESI-MS: m/z
414 ([M + H]+), 436 ([M + Na]+).
4.2.5. General Procedure for ALA Coupling to Pyridinones. N-
Benzyloxycarbonyl-5-aminolevulinic acid (2.2 mmol) was dissolved in
DCM (20 mL) and DMF (5 mL) under argon, DCC (2 mmol), and
DMAP (0.2 mmol). The mixture was left to stir for 50 min at room
temperature. Compound 4 (2 mmol) was dissolved in DCM (10 mL)
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and added dropwise over 30 min. The mixture was stirring overnight
at room temperature. The heavy precipitate was ﬁltered oﬀ, and the
solvents were evaporated in vacuo. The residue was dissolved in DCM
and washed with water then saturated sodium hydrogen carbonate.
The solvent was removed, and the residue was puriﬁed by ﬂash
chromatography on silica gel using a gradient of petroleum ether/ethyl
acetate (1:4), followed by 100% ethyl acetate and then methanol/ethyl
acetate (1:9). The products 6 were isolated as yellow pastes with yields
of 72−80%.
2-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl-5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6a). Yield 77%. 1H
NMR (CDCl3, 270 MHz) δ 0.95 (t, J = 7.6 Hz, 3H CH3), 2.47 (m,
2H, CH2), 2.55 (m, 2H, CH2), 2.59 (q, J = 7.6 Hz, 2H, CH2), 3.95 (m,
4H, CH2), 4.12 (s, 2H, CH2), 5.01 (s, 2H, CH2), 5.14 (s, 2H, CH2),
6.30 (s, 1H, NH), 6.32 (d, J = 7.4, 1H, C5-H in pyridinone), 7.2−7.36
(m, 11H, 10H from 2Ph and 1H from C6-H in pyridinone). 13C
NMR: δ 13.2, 17.7, 27.7, 34.5, 49.9, 50.6, 62.6, 66.8, 71.7, 117.2, 123.3,
127.9, 128.1, 128.3, 128.6, 128.7, 136.1, 138.5, 142.0, 142.4, 146.2,
156.2, 173.1, 173.5, 206.7. ESI-MS: m/z 521 ([M + H]+), 543 ([M +
Na]+).
4-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)butyl-5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6b). Yield 79%. 1H
NMR (CDCl3, 270 MHz) δ 0.95 (t, J = 7.6 Hz, 3H CH3), 1.52 (m,
2H, CH2), 1.67 (m, 2H, CH2), 2.47 (m, 2H, CH2), 2.49 (m, 2H,
CH2), 2.52 (q, J = 7.6 Hz, 2H, CH2), 3.63 (m, 2H, CH2), 3.93 (m, 4H,
CH2), 4.98 (s, 2H, CH2), 5.11 (s, 2H, CH2), 6.01 (s, 1H, NH), 6.31
(d, J = 7.4, 1H, C5-H in pyridinone), 7.19−7.22 (m, 11H, 10H from
2Ph and 1H from C6-H in pyridinone). 13C NMR: δ 13.3, 25.7, 26.3,
27.9, 28.5, 29.1, 31.5, 50.7, 53.3, 64.8, 66.9, 72.9, 76.8, 117.4, 127.9,
128.1, 128.2, 128.3, 128.6, 128.7, 136.2, 138.5, 145.2, 156.3, 172.5,
173.4, 204.0. ESI-MS: m/z 549 ([M + H]+). 571 ([M + Na]+).
6-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl-5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6c). Yield 80%. 1H
NMR (CDCl3, 270 MHz) δ 0.98 (t, J = 7.6 Hz, 3H, CH3), 1.21−1.23
(m, 4H, CH2), 1.52−1.55(m, 4H, CH2), 2.44−2.47 (m, 4H, CH2),
3.63 (q, J = 7.4 Hz, 2H, CH2), 3.84−3.98 (m, 6H, CH2), 5.01 (s, 2H,
CH2), 5.11 (s, 2H, CH2), 6.02 (br, 1H, NH), 6.31 (d, J = 7.4, 1H, C5-
H in pyridinone), 7.18 (d, J = 7.4 Hz, C6-H in pyridinone), 7.21 (m,
10H, Ph). 13C NMR: δ 13.9, 19.5, 25.7, 26.7, 27.5, 28.9, 29.2, 29.3,
29.4, 31.7, 34.5, 49.9, 50.7, 52.6, 65.0, 67.0, 71.2, 117.5 127.9, 128.2,
128.8 136.4, 138.1, 138.5, 142.0, 156.2, 172.5, 173.1, 206.7. ESI-MS:
m/z 577 ([M + H]+), 599 ([M + Na]+).
8-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octyl 5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6d). Yield 75%.
1H NMR (CDCl3, 270 MHz) δ 1.02 (t, J = 7.6 Hz, 3H, CH3), 1.29
(m, 8H, CH2), 1.63 (m, 4H, CH2), 2.55−2.70 (m, 6H, CH2), 3.75 (m
2H, CH2), 4.03−4.13 (m, 4H, CH2), 5.09 (s, 2H, CH2), 5.25 (s, 2H,
CH2), 5.57 (br, 1H, NH), 6.49 (d, 1H, J = 7.4 Hz, 1H, C5-H in
pyridinone), 7.28−7.64 (m, 11H, 2Ph and C6-H in pyridinone). 13C
NMR: δ 13.4, 20.2, 25.9, 26.5, 27.9, 28.2, 28.6, 29.2, 29.3, 29.4, 31.5,
50.7, 53.3, 64.8, 67.0, 72.9, 117.5, 127.9, 128.1, 128.3, 128.5, 128.6,
128.8, 134.2, 137.9, 138.1, 146.8, 156.3, 172.6, 173.6, 204.1. ESI-MS:
m/z, 605 ([M + H]+), 627 ([M + Na]+).
10-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)decyl 5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6e). Yield 72%.
1H NMR (CDCl3, 270 MHz) δ 1.02 (t, J = 7.6 Hz, 3H, CH3), 1.24
(m, 12H, CH2), 1.56 (m, 4H, CH2), 2.51−2.66 (m, 6H, CH2), 3.7 (m,
2H, CH2), 4.01−4.09 (m, 4H, CH2), 4.95 (s, 2H, CH2), 5.23 (s, 2H,
CH2), 5.69 (br, 1H, NH), 6.36 (d, J = 7.4, 1H, C5-H in pyridinone),
7.12 (d, J = 7.4, 1H, C6-H in pyridinone), 7.26−7.31 (m, 10H, Ph).
13C NMR: δ 13.4, 20.3, 25.9, 26.5, 27.3, 27.9, 28.2, 28.6, 28.9, 29.2,
29.3, 29.4, 31.5, 50.7, 53.3, 64.8, 67.0, 72.9, 117.5, 127.9, 128.1, 128.3,
128.5, 128.6, 128.8, 134.2, 137.9, 138.1, 146.2, 156.3, 172.6, 173.6,
204.1. ESI-MS: m/z 633 ([M + H]+), 655 ([M + Na]+).
12-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)dodecyl 5-
(((benzyloxy)carbonyl)amino)-4-oxopentanoate (6f). Yield 73%.
1H NMR (CDCl3, 270 MHz) δ 0.98 (t, J = 7.6 Hz, 3H, CH3), 1.03
(m, 16H, CH2), 1.57−1.60 (m, 4H, CH2), 2.53−2.64 (m, 6H, CH2),
3.71 (q, J = 7.4 Hz, 2H, CH2), 4.02 (m, 2H, CH2), 4,11 (s, 2H, CH2),
5.06 (s, 2H, CH2), 5.24 (s, 2H, CH2), 5.59 (br, 1H, NH), 6.40 (d, J =
7.4 Hz, 1H, C5-H in pyridinone), 7.28 (d, J = 7.4 Hz, 1H, C6-H in
pyridinone), 7.30−7.39 (m, 10H, Ph). 13C NMR: δ 13.3, 20.1, 25.9,
26.4, 27.6, 28.2, 28.6, 28.9, 29.2, 29.4, 29.5, 29.7, 31.6, 50.7, 53.3, 60.5,
65.0, 67.0, 72.9, 117.5, 128.8, 127.9, 128.1, 128.2, 128.6, 128.8, 136.5,
137.9, 138.7, 145.6, 156.3, 172.5, 173.6, 204.1. ESI-MS: m/z 661 ([M
+ H]+), 683 ([M + Na]+).
4.2.6. General Procedure for the Deprotection of Amino and
Hydroxyl Groups of ALA−HPO Conjugates. Compounds 6a−6f, 11,
17, and 22 (1 equiv) were dissolved in methanol/ethyl acetate (50 mL,
1:4). Catalytic amount of palladium on carbon (5% Pd/C, 10% weight
of protected ALA−HPO conjugates) and benzyl chloride (2.2 equiv)
were added. The hydrogenation was carried out under 40 psi H2 at
room temperature for 10 min. Pd/C was ﬁltered oﬀ, and the ﬁltrate
was evaporated to dryness. The residues were puriﬁed by semi-
preparative Agilent HPLC using reverse-phase Waters column (4.6
mm × 250 mm) eluted with acetonitrile/methanol (30:70, V/V) with
ﬂow rate 1 mL/min. ALA−HPO conjugates 7, 12, 18, and 23 were
isolated as thick oils. The purity of all compounds was determined by
analytical HPLC (Agilent system 1100) coupled with UV−vis/DAD
using C18 reverse-phase column [HYPERSIL (5 μm, 2.1 mm × 150
mm)]. The mobile phase was A (0.1% TFA in MeOH:H2O, 2:98),
100% isocratic for 5 min, B (0.1% TFA in MeOH:H2O, 98:2), gradient
from 0 to 50% between 6 and 10 min, 50% B isocratic from 11 to 15
min, then equilibrated with 100% A for 2 min. The total elution time
was 18 min and ﬂow rate was 0.25 mL/min. The total run was
monitored with UV detector at two wavelengths 268 and 282 nm.
(2-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)ethoxy)-2,5-dioxo-
pentan-1-aminium Chloride (7a). The product was isolated as thick
oil, yield 35%, HPLC-DAD (Rt: 2.3 min; purity 95.6%).
1H NMR
(DMSO, 270 MHz) δ 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.64 (m, 2H,
CH2), 2.85 (m, 2H, CH2), 3.06 (m, 2H, CH2), 3.59 (m, 2H, CH2),
4.02 (s, 2H, CH2), 4.38 (m, 2H, CH2), 7.13 (d, J = 6.7 Hz, 1H, C5-H
in pyridinone), 7.66 (m, 3H, H3N
+), 8.10 (d, J = 6.9 Hz, 1H, C6-H in
pyridinone). 13C NMR: δ 12.1, 15.3, 27.7, 36.2, 44.3, 53.7, 55.5, 113.3
127.9, 134.0, 143.0, 164.9, 172.1, 206.2. ESI-MS: m/z 297 ([M + H]+).
HRMS: calcd for C14H21N2O5, 297.1450 ([M + H]
+); found,
297.1441.
5-(4-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)butoxy)-2,5-dioxo-
pentan-1-aminium Chloride (7b). Yield 42%, HPLC-DAD (Rt: 3.2
min; purity 96.3%). 1H NMR (CD3OH, 270 MHz) δ 1.26 (t, J = 7.1
Hz, 3H, CH3), 1.82 (m, 2H, CH2) 1.98 (m, 2H,CH2), 2.64 (m, 2H,
CH2), 2.83 (m, 2H, CH2), 3.06 (q, J = 5.4 Hz, 2H, CH2), 4.09 (m, 4H,
CH2), 4.43 (m, 2H, CH2), 7.12 (d, J = 6.4 Hz, 1H, C5-H in
pyridinone), 8.32 (d, J = 6.7 Hz, 1H, C6-H in pyridinone). 13C NMR:
δ 11.1, 15.3, 19.4, 26.8, 27.1, 36.2, 50.3, 52.6, 64.4, 116.8, 126.2, 137.4,
140.5, 156.2, 172.2, 201.2. ESI-MS: m/z 325 ([M + H]+), 347 ([M +
Na]+). HRMS: calcd for C16H25N2O5, 325.1763 ([M + H]
+); found,
325.1743.
5-((6-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)oxy)-2,5-di-
oxopentan-1-aminium Chloride (7c). Yield 42%, HPLC-DAD (Rt:
3.7 min; purity 96.6%). 1H NMR (CD3OH, 270 MHz) δ 1.29 (t, J =
7.1 Hz, 3H, CH3), 1.45 (m, 4H, CH2) 1.89 (m, 4H, CH2), 2.67 (m,
4H, CH2), 2.82 (m, 2H, CH2), 3.29 (m, 2H, CH2), 3.55 (m, 2H,
CH2), 4.06 (m, 2H, CH2), 7.15 (d, J = 6.4 Hz, 1H, C5-H in
pyridinone), 8.20 (d, J = 6.7 Hz, 1H, C6-H in pyridinone). 13C NMR:
δ 11.1, 15.2, 19.4, 25.4, 26.8, 29.1, 34.2, 36.2, 50.3, 52.6, 64.4, 111.9
136.4, 138.5, 156.2, 172.2, 173.1, 201.2. ESI-MS: m/z 353.3 ([M +
H]+), 375.3 ([M + Na]+). HRMS: calcd for C18H29N2O5, 353.2076
([M + H]+); found, 353.2065.
5-((8-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)octyl)oxy)-2,5-di-
oxopentan-1-aminium) Dichloride (7d). Yield 48%, HPLC-DAD (Rt:
4.3 min; purity 97.7%). 1H NMR (CD3OH, 270 MHz) δ 1.17 (t, 3H, J
= 7.1 Hz, CH3), 1.26 (m, 12H, CH2), 2.66 (m, 2H, CH2), 2.85 (m,
2H, CH2), 3.49 (m, 2H, CH2), 3.61, (m, 2H, CH2), 4.05−4.11 (m,
4H, CH2), 7.33 (d, J = 6.4 Hz, 1H, C5-H in pyridinone) 8.22 (d, J =
6.7 Hz, 1H, C6-H in pyridinone). 13C NMR: δ 11.3, 19.9, 25.7, 26.4,
29.0, 29.1, 31.3, 34.2, 36.2, 50.3, 52.6, 64.4, 110.8 138.4, 143.4, 146.4,
158.4, 172.9, 201.7. ESI-MS: m/z 382.1 ([M + H]+), 404.2 ([M +
Na]+). HRMS: calcd for C20H33N2O5, 381.2389 ([M + H]
+); found,
381.2383.
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5-((10-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)decyl)oxy)-2,5-
dioxopentan-1-aminium Chloride (7e). Yield 45%, HPLC-DAD (Rt:
5.4 min; purity 97.4%). 1H NMR (CD3OH, 270 MHz) δ 1.17 (t, J =
7.1 Hz, 3H, CH3), 1.26 (m, 16H, CH2), 2.66 (m, 2H, CH2), 2.85 (m,
2H, CH2), 3.15 (m, 2H, CH2), 3.91 (m, 2H, CH2), 4.05 (s, 2H, CH2),
4.60 (m, 2H, CH2), 7.15 (d, J = 6.4 Hz, 1H, C5-H in pyridinone), 8.20
(d, J = 6.7 Hz, 1H, C6-H in pyridinone). 13C NMR: δ 11.3, 19.8, 25.0,
26.4, 29.0, 29.1, 29.3, 31.2, 34.2, 50.3, 52.6, 56.4, 61.7, 64.7, 110.8,
138.4, 143.5, 146.0, 158.2, 172.9, 201.2. ES-MS: 409.2 ([M + H]+).
HRMS: calcd for C22H37N2O5, 409.2702 ([M + H]
+); found,
409.2700.
5-((12-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)dodecyl)oxy)-
2,5-dioxopentan-1-aminium Chloride (7f). Yield 43%, HPLC-DAD
(Rt: 6.2 min; purity 96.8%).
1H NMR (CD3OH, 270 MHz) δ 1.11 (t, J
= 7.1 Hz, 3H, CH3), 1.13 (m, 20H, CH2), 2.66 (m, 2H, CH2), 2.90
(m, 2H, CH2), 3.32 (m, 2H, CH2), 3.91 (m, 2H, CH2), 4.09 (s, 2H,
CH2), 4.60 (m, 2H, CH2), 7.33 (d, J = 6.4 Hz, 1H, C5-H in
pyridinone), 8.22 (d, J = 6.7 Hz, 1H, C6-H in pyridinone). 13C NMR:
δ 11.3, 19.8, 25.7, 26.1, 28.7, 28.9, 29.0, 29.1, 29.3, 31.3, 32.4, 34.2,
50.2, 52.3, 56.4, 61.7, 64.7, 110.7, 138.1, 143.5, 146.4, 158.4, 172.9,
201.2. ESI-MS: m/z 437.0 ([M + H]+), 459.1 ([M + Na]+). HRMS:
calcd for C24H41N2O5, 437.3015 ([M + H]
+); found, 437.3025.
4.2.7. Synthesis of ALA−HPO Conjugate 12. 3-(Benzyloxy)-2-(1-
hydroxyethyl)-4H-pyran-4-one (8). A mixture of 3-(benzyloxy)-2-
ethyl-4H-pyran-4-one (2a) (10g, 43.4 mmol), SeO2 (14.5 g, 130.4
mmol), and phenyl bromide (50 mL) was heated to 135−140 °C with
vigorous stirring for 4 h. After ﬁltration, the ﬁltrate was concentrated
and the residue was puriﬁed by column chromatography using ethyl
acetate/cycle hexane (2:1) as an eluent to obtain product as a brown
oil (4.6 g, 43%). 1H NMR (CDCl3, 400 MHz) δ 1.23 (d, J = 6.7 Hz,
3H, CH3), 4.85 (q, J = 6.7 Hz, 1H, CH), 5.22 (d, J = 2.0 Hz, 2H,
CH2), 6.46 (d, J = 5.6 Hz, 1H, C5-H in pyridinone), 7.37 (m, 5H, Ph),
7.71 (d, J = 5.6 Hz, 1H, C6-H in pyridinone). ESI-MS: m/z 247 ([M +
H]+).
3-(Benzyloxy)-2-(1-(benzyloxy)ethyl)-4H-pyran-4-one (9). To a
solution of 3-(benzyloxy)-2-(1-hydroxyethyl)-4H-pyran-4-one (8)
(4.0 g, 16.2 mmol) in dichloromethane (50 mL) was added 50%
KOH (5.45g, 48.6 mmol) and Bu4N
+HSO4
− (0.1 g). The mixture was
stirred at room temperature for 30 min before benzyl bromide (4.17g,
24.4 mmol) was added dropwise. The reaction was monitored by TLC
until the starting material disappeared. The reaction mixture was
washed with brine, and the organic layer was dried over anhydrous
Na2SO4. After removal of the solvent, the residue was puriﬁed by
column chromatography using ethyl acetate/cycle hexane (1:2) as an
eluent to obtain product 9 as a pale-yellow oil (3.4 g, 62%). 1H NMR
(CDCl3, 400 MHz) δ 1.14 (d, J = 6.6 Hz, 3H, CH3), 4.19−4.28 (m,
2H, CH2), 4.67 (q, J = 6.6 Hz, 1H, CH), 5.19 (s, 2H, CH2), 6.40 (d, J
= 5.6 Hz, 1H, C5-H in pyridinone), 7.24−7.33 (m, 10H, Ph), 7.71 (d,
J = 5.6 Hz, 1H, C6-H in pyridinone). ESI-MS: m/z 337 ([M + H]+).
3-(Benzyloxy)-2-(1-(benzyloxy)ethyl)-1-(6-hydroxyhexyl)pyridin-
4(1H)-one (10). The synthetic procedure was similar to that adopted
for the preparation of 4. Yield: 66%. 1H NMR (CDCl3, 400 MHz) δ
1.14−1.29 (m, 4H, CH2), 1.22 (d, J = 7.0 Hz, 3H, CH3), 1.44 (m, 2H,
CH2), 1.62 (m, 2H, CH2), 3.56 (t, J = 6.5 Hz, 2H, CH2), 3.98 and 4.10
(m, 2H, CH2), 4.16 (s, 2H, CH2), 5.26 (s, 2H, CH2), 6.48 (d, J = 7.5
Hz, 1H, C5-H in pyridinone), 7.21 (m, 3H, Ph and buried C6-H in
pyridinone), 7.28−7.34 (m, 8H, Ph). ESI-MS: m/z 436 ([M + H]+),
458 ([M + Na]+).
6-(3-(Benzyloxy)-2-(1-(benzyloxy)ethyl)-4-oxopyridin-1(4H)-yl)-
hexyl-5-((benzyloxycarbonyl)amino)-4-oxopentanoate (11). 1H
NMR (CDCl3, 270 MHz) δ 1.22 (m, 7H, 2CH2 and CH3), 1.44−
1.59 (m, 4H, 2CH2), 2.58−2.69 (m, 4H, 2CH2), 3.93−4.14 (m, 7H,
3CH2 and CH), 5.09 (s, 2H, CH2), 5.22 (s, 4H, 2CH2), 5.63 (s, 1H,
NH), 6.46 (d, J = 7.4 Hz, 1H, C5-H in pyridinone), 7.38−7.47(m,
15H, 3Ph), 8.82 (d, J = 7.4 Hz, 1H, C6-H in pyridinone). 13C NMR: δ
20.4, 25.6, 26.2, 27.7, 27.8, 28.4, 31.7, 34.5, 50.7, 52.3, 64.6, 66.7, 67.0,
69.7, 71.2, 74.7, 117.9, 127.6, 128.2, 128.3, 128.5, 128.5, 129.4, 137.5,
138.5, 140.0, 144.5, 146.0, 156.3, 172.5, 173.8, 206.7. ESI-MS: m/z
683 ([M + H]+), 705 ([M + Na]+).
5-((6-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)oxy)-2,5-di-
oxopentan-1-aminium Chloride (12). The product was isolated as
thick oil, yield 35%, HPLC-DAD (Rt: 3.5 min; purity 96.5%).
1H
NMR (CD3OH, 270 MHz) δ 1.20−1.44 (m, 7H, 2CH2 and CH3),
1.93−2.06 (m, 4H, CH2), 2.66 (m, 2H, CH2), 2.81 (m, 2H, CH2),
3.57 (m, 2H, CH2), 4.09 (m, 4H, 2CH2), 5.67 (m, 1H, CH), 7.19 (d, J
= 6.4 Hz, 1H, C5-H in pyridinon), 8.21 (d, J = 6.7 Hz, 1H, C6-H in
pyridinon). 13C NMR: δ 13.9, 19.4, 25.4, 26.8, 27.1, 34.23, 36.2, 50.3,
52.6, 64.4, 72.2, 116.8, 126.2, 137.4, 141.5, 156.2, 173.1, 201.2. ESI-
MS: 369.2 ([M + H]+), 391.2 ([M + Na]+). HRMS: calcd for
C18H29N2O6, 369.2026 ([M + H]
+); found, 369.2019.
4.2.8. Synthesis of ALA−HPO Conjugate 18. 3-(Benzyloxy)-N-
methyl-4-oxo-4H-pyran-2-carboxamide (15). A solution of 3-
(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 14 (0.94g, 3.82 mmol)
and N-hydroxysuccimide (0.485g, 4.2 mmol) in tetrahydrogenfuran
(20 mL) was stirred at room temperature for 30 min. DCC (0.866g,
4.2 mmol) was added, and the stirring was continued for 5 h.
Methylamine (2 M in THF, 4.58 mmol) was added, and the solution
was stirred at room temperature overnight. After ﬁltration, the ﬁltrate
was concentrated and the residue was puriﬁed by column
chromatography using ethyl acetate/methanol (9:1) as an eluent to
obtain product (0.85g, 86%). 1H NMR (CDCl3, 400 MHz) δ 2.78 (d,
J = 5.0 Hz, 3H, CH3), 5.39 (s, 2H, CH2), 6.49 (d, J = 5.6 Hz, 1H, C5-
H in pyridinone), 7.40 (m, 5H, Ph), 7.70 (br, 1H, NH), 7.84 (d, J =
5.6 Hz, 1H, C6-H in pyridinone). ESI-MS: m/z 260 ([M + H]+).
3-(Benzyloxy)-1-(6-hydroxyhexyl)-N-methyl-4-oxo-1,4-dihydro-
pyridine-2-carboxamide (16). 1H NMR (CDCl3, 400 MHz) δ 1.30−
1.42 (m, 4H, CH2), 1.55 (m, 2H, CH2), 1.76 (m, 2H, CH2), 2.73 (d, J
= 4.9 Hz, 3H, CH3), 3.62 (t, J = 6.3 Hz, 2H, CH2), 3.83 (t, J = 7.5 Hz,
2H, CH2), 5.09 (s, 2H, CH2), 6.30 (d, J = 7.4 Hz, 1H, C5-H in
pyridinone), 7.13 (d, J = 7.4 Hz, 1H, C6-H in pyridinone), 7.31 (m,
5H, Ph), 7.43 (m, 1H, NH). ESI-MS: m/z 359 ([M + H]+), 381 ([M
+ Na]+).
6-(3-(Benzyloxy)-2-(methylcarbamoyl)-4-oxopyridin-1(4H)-yl)-
hexyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate (17). The
product was isolated as yellow paste, yield 80%. 1H NMR (CDCl3, 270
MHz) δ 1.30 (m, 4H, 2CH2), 1.57 (m, 2H, CH2), 1.74 (m, 2H, CH2),
2.60−2.68 (m, 4H, 2CH2), 2.70 (d, J = 2.9 Hz, 3H, CH3), 2.76 (m,
2H, CH2) 4.02 (m, 4H, 2CH2), 4.98 (s, 2H, CH2), 5.06 (s, 2H, CH2),
5.71 (br, 1H, NH), 6.20 (d, J = 7.4, 1H, C5-H in pyridinone), 7.25 (d,
J = 7.4 Hz, C6-H in pyridinone), 7.27−7.32 (m, 10H, 2Ph), 8.01 (br,
H, NH). 13C NMR: δ 25.1, 25.4, 26.0, 26.3, 27.9, 28.4, 31.7, 34.5, 50.1,
54.9, 64.6, 67.7, 74.2, 118.0, 128.0, 128.1, 128.3, 128.6, 134.9, 136.8,
138.5, 140.1, 145.8, 156.2, 161.6, 172.5, 173.8, 204.3. ESI-MS: m/z
606 ([M + H]+), 628 ([M + Na]+).
5-((6-(3-Hydroxy-2-(methylcarbamoyl)-4-oxopyridin-1(4H)-yl)-
hexyl)oxy)-2,5-dioxopentan-1-aminium Chloride (18). The product
was isolated as thick oil, yield 37%, HPLC-DAD (Rt: 3.4 min; purity
97.0%). 1H NMR (CD3OH, 270 MHz) δ 1.52 (m, 4H, 2CH2), 1.64
(m, 2H, CH2), 2.07 (m, 2H, CH2), 2.67 (m, 2H, CH2), 2.83 (m, 2H,
CH2), 3.28 (s, 3H, CH3), 4.02−4.07 (m, 4H, 2CH2), 4.35 (m, 2H,
CH2), 7.26 (d, J = 6.4 Hz, 1H, C5-H in pyridinone), 8.30 (d, J = 6.7
Hz, 1H, C6-H in pyridinone). 13C NMR: δ 25.0, 25.5, 26.1, 27.2, 27.9,
28.1, 34.0, 50.1, 59.2, 64.6, 112.0, 136.5, 138.7, 143.0, 162.5, 158.2,
172.8, 201.8. ESI-MS: m/z 382.2 ([M + H]+), 404.4 ([M + Na]+).
HRMS: calcd for C18H28N3O6, 382.1978 ([M + H]
+); found,
382.1966.
4.2.9. Synthesis of ALA−HPO Conjugate 23. 2-(2-(2-
Aminoethoxy)ethoxy)ethanol (20). The synthetic procedure was
similar to that of 3. 1H NMR (CDCl3, 400 MHz) δ 2.19 (br, 2H,
NH2), 2.88 (t, J = 5.1 Hz, 2H, CH2), 3.55 (t, J = 5.1 Hz, 2H, CH2),
3.60−3.74 (m, 8H, CH2). ESI-MS: m/z 150 ([M + H]+).
1-(2-(2-Hydroxyethoxy)ethyl)-3-(benzyloxy)-2-ethylpyridin-4(1H)-
one (21). The synthetic procedure was similar to that of 4. 1H NMR
(CDCl3, 400 MHz) δ 1.00 (t, J = 7.5 Hz, 3H, CH3), 2.63 (q, J = 7.5
Hz, 2H, CH2), 3.54 (m, 6H, CH2), 3.66−3.73 (m, 4H, CH2), 3.98 (t, J
= 5.2 Hz, 2H, CH2), 5.25 (s, 2H, CH2), 6.43 (d, J = 7.6 Hz, 1H, C5-H
in pyridinone), 7.28−7.35 (m, 4H, Ph and buried C6-H in
pyridinone), 7.44 (m, 2H, Ph). ESI-MS: m/z 362 ([M + H]+), 384
([M + Na]+).
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2-(2-(2-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethoxy)-
ethoxy)ethyl-5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate
(22). The product was isolated as thick oil, yield 70%. 1H NMR
(CDCl3, 270 MHz) δ 0.98 (t, 3H, CH3), 2.59−2.61 (m, 6H, 3CH2),
3.47−3.73 (m, 8H, 4CH2), 3.90 (m, 2H, CH2), 4.04 (s, 2H, CH2),
4.30 (m, 2H, CH2), 5.05 (s, 2H, CH2), 5.19 (s, 2H, CH2), 5.90 (br, H,
NH), 6.35 (d, 1H, J = 7.4 Hz, 1H, C5-H in pyridinone), 7.23−7.27
(m,10H, 2Ph), 7.38 (d, J = 7.4 Hz, 1H, C6-H pyridinone). 13C NMR:
δ 13.2, 19.5, 27.5, 27.9, 34.2, 50.7, 52.6, 63.8, 70.6, 70.9, 71.3, 72.9,
117.1, 128.3, 128.7,136.5, 137.9, 138.0, 139.4, 145.7, 146.0, 156.5,
172.4, 173.7, 204.6. ESI-MS: m/z 609 ([M + H]+), 631 ([M + Na]+).
5-(2-(2-(2-(2-Ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)ethoxy)-
ethoxy)ethoxy)-2,5-dioxopentan-1-aminium Chloride (23). The
product was isolated as thick oil, yield 37%, HPLC-DAD (Rt: 2.8
min; purity 95.8%). 1H NMR (CD3OH, 270 MHz) δ 1.17 (t, J = 7.1
Hz, 3H, CH3), 2.56 (m, 2H, CH2), 2.73 (m, 2H, CH2), 3.01 (q, J = 5.4
Hz, 2H, CH2), 3.21 (m, 2H, CH2), 3.47 (m, 6H, 3CH2), 3.54 (m, 2H,
CH2), 3.90 (s, 2H, CH2), 4.65 (m, 2H, CH2), 7.07 (d, J = 6.4 Hz, 1H,
C5-H in pyridinon), 8.08 (d, J = 6.7 Hz, 1H, C6-H in pyridinone). 13C
NMR: δ 13.9, 19.4, 25.4, 27.1, 34.23, 36.2, 26.8, 50.3, 52.6, 64.4, 72.2,
116.8 126.2, 137.4, 141.5.4, 156.2, 173.1, 204.2. ESI-MS: m/z 385 ([M
+ H]+), 407 ([M + Na]+). HRMS: calcd for C18H29N2O7, 385.1975
([M + H]+); found, 385.1968.
4.3. Cell Culture. The human breast adenocarcinoma cell line
MCF-7, doxorubicin-resistant counterpart MCF-7R line (donated by
Dr Marilena Loizidou, UCL), and the human oral epidermal
carcinoma KB cell line purchased from ATCC were employed for
this study. Both MCF-7 and MCF-7R cell lines were cultured in
DMEM-F12 containing L-glutamine (20 μM) and phenol red. KB cells
were cultured in Eagle’s Minimum Essential Medium (EMEM)
containing L-glutamine (20 μM), phenol red, and nonessential amino
acid (5 mL). The media for all cell lines was supplemented with
gentamicin (500 units/mL; Life Technologies) and 10% fetal calf
serum, and it was standardized to give an iron concentration between
450 and 600 μg/100 g in order to reach the physiological iron levels in
biological systems.30 The cells were grown as monolayers in sterile,
vented-capped, angle-necked cell culture ﬂasks (Corning) and were
maintained at 37 °C in a humidiﬁed 5% CO2 incubator (IR Autoﬂow
Water-Jacketed Incubator; Jencons Nuaire) until conﬂuent.
4.3.1. Fluorescence Pharmacokinetics and Mechanistic Study.
Cells were seeded into γ-sterilized 96-well plates (Orange Scientiﬁc,
Triple Red Laboratory Technologies) at a density of ∼5 × 104 per well
for 48 h. The culture medium was removed, and the cells were washed
with PBS. The cells were incubated with freshly prepared solutions of
ALA and ALA−HPOs derivatives: 100 μL serum-free medium
containing varying prodrugs concentrations was added to a designated
series of wells. Each plate contained wells with cells without prodrug as
control for subtracting the natural PpIX ﬂuorescence reading. PpIX
ﬂuorescence induced by ALA and ALA−HPOs derivatives was
measured from each well with a PerkinElmer LS 50B ﬂuorescence
spectrometer coupled to an automated plate reader (PerkinElmer)
using 405 nm excitation and 635 nm emission wavelengths with slit
widths set to 10 nm and the internal 515 nm long-pass ﬁlter used on
the emission side. The spectral scans were recorded between 600 and
750 nm, discriminating PpIX from other porphyrins, should any be
present. The mean ﬂuorescence intensity (expressed in arbitrary units)
was calculated after subtraction the control values. Time course
measurements for PpIX ﬂuorescence intensities were recorded with
ALA or ALA−HPOs over periods of 2, 4, 6, and 24 h with
concentration varied between 1 and 100 μM.
Study on Dependence of ALA Transport on Temperature.
Temperature dependent study was conducted for cellular uptake of
prodrugs. MCF-7R and KB cells were seeded in two 96-well γ-
irradiated plates, incubated for 48 h, and washed with PBS. ALA and
ALA−HPOs prodrugs (500 μM) in clear medium were added at 100
μL/well, and the plates were wrapped in foil. One plate was incubated
at 37 °C and the other at 4 °C for 1 h. The prodrugs were then
removed, cells were rinsed in PBS, and 100 μL of clear medium was
added to each well. The plates were both incubated at 37 °C for 4 h to
allow the ALA already taken up by the cells to be converted to PpIX.
The amount of PpIX produced by the cells in the diﬀerent conditions
was evaluated as described above.
4.3.2. Photodynamic Treatment. Cells were seeded into 96-well
plates at a density of ∼5 × 104 per well. Following incubation for 48 h,
the cells were washed with PBS and 100 μL solutions containing each
compound at varying concentrations (between 1 and 100 μM) were
added to their designated wells for set incubation periods. Each well
plate contained three control wells without the compound and the
compound at ﬁve diﬀerent concentrations in triplicate. The plates were
irradiated with a ﬂuence of 2.5 J/cm2 using a LumiSource lamp (PCI
Biotech), which emits a uniform ﬁeld of low-power blue light over an
area of 14 cm × 32 cm. Peak output was ∼420 nm, which overlapped
with the PpIX Soret band. Immediately following irradiation, the
medium was replaced and cells were incubated for further 18 h. Cell
cytotoxicity at 24 h after treatment was determined using the 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay:
cells were incubated with medium containing MTT (1 mg/mL
dissolved in full DMEM-12 for MCF-7 and MCF-7R, EMEM for KB)
for 2 h. The insoluble end product (formazan derivatives) was
dissolved in 100 μL of DMSO after removing the medium.
Absorbance was quantiﬁed at 570 nm using a 96-well plate reader
(ELX800, BioTek Instruments). The mean cell survival was calculated
for each prodrug at every concentration tested and expressed as a
percentage of control cell survival values. Control wells contained cells
without compounds and allocated in the same plate with the other
compounds that were irradiated for phototoxicity experiments. For
determination of “dark” toxicity of the compounds, well plates were
prepared in the same manner as above but without irradiation.
4.3.3. Determination of Intracellular PpIX Content. Cells were
seeded into 100 mm Petri dishes at a density of 5 × 104 cells per well
for 48 h at 37 °C. The culture medium was removed, and the cells
were washed with PBS. The cells were then incubated with the 100 μL
of ALA or the selected ALA−HPO prodrugs for 4 h and then washed
twice with PBS. CelLytic (Sigma-Aldrich) (1 mL) was added and
incubated for 15 min at room temperature, and the cells were scraped
and collected in cryostat vials. Cell extracts were centrifuged at 1800g
for 10 min to remove the cell debris, and the supernatant containing
the PpIX was collected. The content of PpIX in the cell lysates was
determined by a ﬂuorescence plate reader (PerkinElmer) in 96-well
plates, with excitation wavelength at 405 nm and emission at
wavelength at 635 nm as reported above. The protein content of
the cells was determined using a bicinchoninic acid protein
determination kit (Sigma-Aldrich). We found that the ﬁnal solution
of the derivatized products after acidic hydrolysis and derivatization
was inhomogeneous; it was causing inconsistent result with HPLC
analysis. Therefore, the ratio of acetylacetone solution was modiﬁed to
increase the percentage of ethanol. The recovery of intracellular
accumulation of ALA from ALA−HPOs was similar to ALA quantities
after acidic hydrolysis for 1 h of incubation in KB and MCF-7R cell
lines. Therefore, ester hydrolysis of the conjugates takes place rapidly
and eﬃciently inside the cells. For all 6 × 24-well test plates, the last
three wells contained control cells not incubated with any compounds
(blank controls). The PpIX ﬂuorescence measurements from these
wells were used to subtract the natural cellular PpIX autoﬂuorescence
from all the other measurements made from the same plate.
4.3.4. Intracellular ALA Determination. Sample Derivatization
and Analysis Procedures. Stock solutions of ALA and ALA−HPO
conjugates in deionized water were prepared and stored at −20 °C.
Working solutions were prepared daily by dilution of the stock
solutions in media without phenol red or serum. Calibration samples
were prepared by spiking blank cell lysate with the appropriate
working solution. The acetylacetone reagent was prepared by mixing
absolute ethanol, water, and acetylacetone in a 45/40/15 volumetric
ratio. Formaldehyde 10% was obtained by dilution of the commercially
available 37% (v/v) aqueous solution in water. The solutions were
stored at 4 °C. The derivatization reactions were performed in a
parallel synthesizer (Acteviotech) equipped with a 16-position reaction
blocks. For the determination of ALA, the calibration samples were
prepared by spiking 90 μL of cell lysate with 10 μL of the appropriate
working solution. For the determination of ALA esters, 350 μL of cell
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lysate was spiked with 50 μL of the appropriate working solution.
Then 200 μL of such a mixture was diluted to 2 mL with 0.01 M HCl
in a 16 mm parallel synthesizer reaction tube. The tubes were
transferred into the Greenhouse reactor preheated at 100 °C, reﬂuxed
for 3 h under stirring, and then cooled in an ice-bath. In an
Acteviotech reaction tube equipped with a magnetic stirrer, 50 μL of
calibration sample was added to 3500 μL of acetylacetone reagent and
450 μL of 10% formaldehyde solution. The tubes were placed in the
parallel synthesizer reactor preheated at 100 °C and stirred for 10 min.
The reactor chamber was wrapped with foil in order to protect the
tubes with the reaction mixture from light. The samples were then
cooled in an ice-bath in the dark for 2 h, transferred into HPLC vials,
and kept in the autosampler at room temperature until the analysis was
performed.
HPLC Fluorescence Analysis. HPLC analysis were performed on a
Agilent system (Life Sciences & Chemical Analysis Group UK),
following the published protocol with some modiﬁcation.49 The
system consisted of a G1311A QuatPump ﬁtted with an internal
vacuum degasser, a WPS-300SL analytical autosampler equipped
H3BDSC10-H column compartment, and a G132A FLD ﬂuorescence
detector. The separations were performed on a Gemini 5 μ C18
H3BDSC10-H column, 100 mm × 2.1 mm (Phenomenex, UK),
equipped with a Security Guard C18 (ODS) 4 mm × 2.1 mm ID
guard column (Phenomenex, UK) at 35 ± 0.1 °C. The mobile phase
consisted of 0.05% formic acid in water (solvent A) and 0.05% formic
acid in methanol (solvent B). The composition of the mobile phase
was as follows: 5.0−0.0 min at 40% solvent B, 0.0−7.0 min at 40%
solvent B, 7.0−7.1 min 40−95% solvent B, 7.1−10.0 min at 95%
solvent B, 10.0−10.1 min 95−40% solvent B. The ﬂow rate was 0.5
mL/min. λexc = 370 nm and λem = 460 nm were used for the detection.
For the low concentration range, 20 μL of sample were injected and
the ﬂuorescence detector was set on high sensitivity. For the high
concentration range, 10 μL were injected and the detector was set on
medium sensitivity. The peak corresponding to 1 eluted at 4.72 min.
The total time required for the analysis was 12.1 min.
4.3.5. Statistical Analysis. All data points and bars in the ﬁgures
represent average values calculated from test solution concentrations
being carried out in triplicate. The results were tabulated or graphically
displayed with error bars representing the standard deviation (SD) of
the mean. Data were analyzed using the unpaired Student’s t-test, and
results with P < 0.05 were considered signiﬁcant.
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